We also confirmed whether changes in HbA1c levels affected BP onset, given that DPP4 inhibitors are antidiabetic agents that are used for type 2 diabetes mellitus treatment owing to their ability to reduce blood glucose levels by inhibiting the degradation of incretin peptides. The gene discussed is GCG; the disease is type 2 diabetes mellitus.